October 29, 2019 — Siemens Healthineers completed the acquisition of 100 percent of Corindus Vascular Robotics Inc., effective Oct. 29, 2019. Prior to the closing of the acquisition, Corindus held a shareholders’ meeting Oct. 25, at which 87.5 percent of their stockholders approved the acquisition. The relevant governmental authorities previously granted the approvals required to complete the acquisition.
"With the completion of the acquisition, we are opening up a new field for our advanced therapies business, tapping into adjacent growth markets with great potential for the future. We are taking an important step forward in the upgrading phase of our 2025 strategy," said Bernd Montag, CEO of Siemens Healthineers AG.
“The combination of Siemens Healthineers’ strong medical technology portfolio with its digital platforms and solutions, together with Corindus’ precision robotics platform, has the potential to transform healthcare delivery so that, together, we can provide better care at lower cost,” said Mark J. Toland, former president and CEO of Corindus. Toland will continue to manage the business within Siemens Healthineers.
Corindus is now part of the advanced therapies reporting segment. Headquartered in Waltham, Mass., the company develops, produces and sells a robotic-assisted platform. It is currently the only U.S. Food and Drug Administration (FDA) cleared and European CE marked robotic system for endovascular coronary and peripheral vascular interventions. It helps physicians to precisely control guide catheters, guidewires, balloon or stent implants via integrated imaging. The physician does not have to stand directly at the angiography table as is current practice but can control the procedure with a separate controlling module and is therefore exposed to less radiation.
Robotic assisted minimally invasive procedures have the potential to reduce treatment times, increase precision during treatment, raise standardization levels in clinical procedures and ultimately improve clinical outcomes. Corindus is currently one of the leading companies offering a robotic treatment platform for major vascular therapeutic markets.
For more information: www.corindus.com
Related Cardiovascular Robotics Content:
First-in-Human Telerobotic Coronary Intervention Procedures Published in EClinicalMedicine
Robocath Successfully Carries Out First Robotic Coronary Angioplasties in Humans
Corindus Vascular Robotics to Be Acquired by Siemens Healthineers
Corindus CorPath GRX Used in Live Complex Robotic-Assisted Coronary Intervention at EuroPCR 2019
Stereotaxis Announces Next-generation Robotic Magnetic Navigation and Imaging Systems
Reducing Physician Radiation Dose With Robotics
Corindus Seeking Neurovascular Intervention Clearance for CorPath GRX Vascular Robotic System
Corindus CorPath Used in World's First-in-Human Telerobotic Coronary Intervention